Stryker invests US$400m in CMR Surgical and secures option to acquire business

pharmafile.com | November 3, 2026 | News story | |  Devices, acquisitions, healthcare market, investment, medical technology 

US medical technology company Stryker is investing approximately US$400m (£300m) in UK surgical robotics developer CMR Surgical, alongside securing an exclusive option to acquire the remaining equity in the business.

The agreement also gives Stryker exclusive US commercial agency rights for CMR’s Versius surgical robotics portfolio, positioning it to expand sales of the system in the world’s largest healthcare market.

CMR will retain responsibility for developing the Versius portfolio and commercialising it outside the US. The companies said the arrangement combines CMR’s surgical robotics technology and clinical experience with Stryker’s commercial reach and established hospital relationships.

Versius is a modular robotic system designed for soft-tissue surgery, with a configuration intended to provide flexibility across procedures and operating environments. The companies said the partnership would help hospitals and ambulatory surgery centres expand their robotic-assisted surgery programmes.

Stryker’s acquisition option would allow it to purchase 100% of CMR’s outstanding equity in a future transaction, subject to the agreement’s terms. Completion of the current transaction is also subject to regulatory approvals and customary closing conditions.

Andy Pierce, Group President of MedSurg and Neurotechnology at Stryker, described soft-tissue robotics as a high-growth opportunity and said the company had selected CMR after evaluating the sector over several years.

Andrew Williamson, Managing Partner at Cambridge Innovation Capital, CMR’s first institutional investor and its largest UK investor, described the deal as a UK technology and manufacturing success. He said the investment would support expansion in the US and other international markets while allowing CMR to retain and grow its UK intellectual property, research and development, jobs and manufacturing infrastructure.

Pic: Marcel Scholte